Differential thyroid cancer after surgery
Conditions
Interventions
Experimental group:The patient will visit the hospital for efficacy assessment 6-12 months after receiving 131I thyroidectomy or adjuvant therapy, or according to the actual clinical situation. The rh
On Day 3 (D3), blood will be drawn to detect indicators such as TSH, and 2-5 mCi of 131I will be taken orally
On Day 5 (D5), blood will be drawn to detect indicators such as sTg, and a whole-body scan (WBS) will be performed.
Sponsors
Tianjin Medical University Cancer Institute and Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1.Aged 18-70 years (inclusive of boundary values) at the time of signing the informed consent form, with no gender restriction; 2.Individuals who have the capacity for conduct, voluntarily participate in this clinical study, and sign the informed consent form; 3.Patients diagnosed with differentiated thyroid cancer (DTC) without distant metastasis, confirmed by pathological diagnosis; 4.Patients who have received 131I ablation therapy or adjuvant therapy for 6-12 months and require efficacy assessment.
Exclusion criteria
Exclusion criteria: 1.Female patients who are pregnant or lactating; 2.Those planning to become pregnant within 6 months; 3.Patients with incompletely healed surgical incisions; 4.Patients allergic to the investigational drugs (rhTSH or 131I) or their excipients; 5.Patients unable to comply with radiation protection requirements; 6.Patients deemed unsuitable for participation in this clinical study by the investigator; 7.Patients with an expected survival period of less than 6 months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Success rate of radioactive iodine ablation or adjuvant therapy; | — |
Secondary
| Measure | Time frame |
|---|---|
| TSH Target Achievement Rate; | — |
Countries
China
Contacts
Public ContactDai Dong
Tianjin Medical University Cancer Institute and Hospital
Outcome results
None listed